Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Treatment With Belimumab Showed Improvement In Symptoms In 46% Of Lupus Patients At 52 Weeks

14.06.2007
Novel endpoint improves assessment of patients with variable disease course

Treatment with belimumab resulted in a sustained improvement of systemic lupus erythematosus (SLE or lupus) disease activity in 46% of patients at week 52, according to a novel combined responder index in results presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

Historically, it has been difficult to adequately measure the therapeutic responses to drug intervention in SLE patients, due to the diverse presentations of the disease itself. A novel combined responder index which takes into account three commonly used measures of disease progression -- SELENA SLEDAI (SS), physician global assessment (PGA) and presence of BILAG-classified flares (new 1A or 2B) -- was utilised by the research team to analyse the effect of the BLyS inhibitor belimumab on the progression of SLE disease activity (see note to Editors).

Lead author Dr Ellen Ginzler, of SUNY-Downstate Medical Center, New York, US, commented: “While the results demonstrated that treatment with belimumab resulted in a sustained improvement in SLE symptoms in patients with serologically active disease, we also confirmed that combining multiple disease activity measures is a successful method of assessing overall disease activity, and appears to be associated with the presence of biomarkers and quality of life improvements in responders.”

Patients enrolled in this 52 week randomised, double-blind, placebo-controlled study received belimumab in doses of 1mg/kg, 4mg/kg and 10mg/kg or placebo plus SLE standard therapy. Overall, ~70% of subjects were taking prednisone and/or anti-malarials such as plaquenil ( used in SLE treatment regimes); 50% of these subjects were also taking an immunosuppressive drug (e.g., methotrexate, azathioprine, mycophenolate, leflunomide). The 449 patients entering the study were evaluated according to the disease activity measurement scores SS and Disease Activity Index, PGA, BILAG, SF-36 and biomarkers including B-cell subsets and autoantibodies. 71.5% of the initial 449 patients entered the study with baseline serological activity. An evidence-based combined endpoint was developed that incorporates a response parameter and controls against worsening in other organ systems.

A combined response, consisting of an improvement in SS score of 4 points or more, with no new BILAG 1A or 2B flares, and no worsening in PGA (

Rory Berrie | alfa
Further information:
http://www.eular.org

More articles from Health and Medicine:

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

nachricht Flexible sensors can detect movement in GI tract
11.10.2017 | Massachusetts Institute of Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Ocean atmosphere rife with microbes

17.10.2017 | Life Sciences

Neutrons observe vitamin B6-dependent enzyme activity useful for drug development

17.10.2017 | Life Sciences

NASA finds newly formed tropical storm lan over open waters

17.10.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>